Immunome : Corporate Presentation

Harnessing the Power

of the Human Memory

B Cell

JANUARY 2023

Immunome, Inc.

665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | immunome.com

Copyright © 2023 Immunome, Inc. All rights reserved.

Disclaimers and Forward-Looking Statements

Copyright © 2023 Immunome, Inc. All rights reserved.

2

This presentation includes certain disclosures that contain "forward-looking statements" intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding our beliefs and expectations regarding the advancement of our oncology and infectious disease programs and platform, execution of our regulatory, clinical and strategic plans, therapeutic potential and benefits of our programs and anticipated upcoming milestones for our programs, as well as the timing and progress of each of the foregoing matters. Forward-looking statements may be identified by the words "anticipate," believe," "estimate," "expect," "intend," "plan," "project," "suggest," "may," "will," "could," "should," "seek," "potential" and similar expressions. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the following: our ability to execute on our strategy, including with respect to R&D efforts, IND submissions and other regulatory filings, timing of these filings and the timing and nature of governmental authority feedback regarding the same, initiation and completion of any clinical studies, confirmatory testing and other anticipated milestones as and when anticipated; the fact that research and development data are subject to differing interpretations and assessments, including during the peer review/publication process in the scientific community and by regulatory authorities; whether our data will be published in a scientific journal and, if so, when and with what modifications; the effectiveness of our

product candidates, including the possibility that further preclinical data and any clinical trial data may be inconsistent with earlier-published data and/or data used for advancing the product candidates; the fact that changes in the profile of the diseases that our programs target could emerge that could impact our ability to address those changes; our ability to fund operations; our reliance on vendors; our ability to execute on our plans for collaborations and partnerships; the competitive landscape; the impact of the COVID-19 pandemic on our business, operations, strategy, goals and anticipated milestones; and the additional risks and

uncertainties set forth more fully under the caption "Risk Factors" in Immunome's Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 28, 2022, and elsewhere in Immunome's Quarterly Reports on form 10-Q and other filings and reports with the SEC.

All statements contained in this presentation are made as of the date specified on the cover, and we undertake no duty to publicly update or revise any such statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

This presentation may contain product names, trade names, trademarks and service marks of Immunome and of other organizations, which are the properties of their respective owners.

Statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this presentation, including independent market research, industry publications and surveys, governmental agency publications and other publicly available information. While we believe that information provides a reasonable basis for these statements, it may be limited or incomplete and we may have not independently verified it. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review or verification of, all relevant information.

We make statements and predictions about future dates for achievement of milestones related to our platform and our programs in this presentation. These statements and predictions involve risks and uncertainties based on various factors and evolution over time and, therefore, actual dates for these milestones may differ.

In this presentation and oral commentary, we may discuss our current and potential future product candidates that have not yet undergone clinical trials or been approved for marketing by the U.S. Food and Drug Administration or other governmental authority. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied. This presentation does not constitute an offering of securities of any kind.

Immunome "At a Glance"

Disruptive Technology Leveraging Human Immune Response

Copyright © 2023 Immunome, Inc. All rights reserved.

Patient Informed Drug Discovery Engine

Significant Partnering Potential

Lead Oncology Program IMM-ONC-01

Rich Research Pipeline

Capital-Efficient Business Strategy

• Interrogates memory B cells, the most educated component of the human immune system
• Potential across multiple therapeutic areas
• AbbVie multi-year research collaboration (up to 10 novel antibody-target pairs)
• U.S. DoD JPEO-CBRND in collaboration with DHA (Antibody cocktail for SARS-CoV-2)
• Antibody targeting IL-38, a novel context dependent immune modulator in multiple solid tumors with poor prognosis
• IND submission anticipated mid-2023
• Antibody targeting EPN1, an ectopically expressed target
• Multiple additional novel targets enabling next-generation modalities (ADCs, T-cell engagers)
• Value creation through partnerships and proprietary programs
• Strong cash position; runway through at least 3Q 2024

3

Strategic Discovery Collaboration with AbbVie

AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets

Copyright © 2023 Immunome, Inc. All rights reserved.

• Immunome will grant AbbVie the option to purchase worldwide rights for up to 10 novel target-antibody pairs arising from three specified tumor types
• Key Financial Terms
• • $30M upfront payment
  • Eligible for additional payments up to:
  • • $70M platform access payments
    • Development and first commercial sale milestones of up to $120M per target
    • Further sales-based milestones
    • Tiered royalties on global sales

Immunome's approach has the potential to unlock novel cancer biology and yield multiple therapeutic candidates

STEVE DAVIDSEN

VP, Oncology Discovery Research, AbbVie

This collaboration with AbbVie, a true leader in the development and commercialization of oncology therapeutics, demonstrates the strength of Immunome's Discovery Engine

PURNANAND SARMA

President & CEO, Immunome

4

B cells: Critical Players in Immunity

Oncology

Copyright © 2023 Immunome, Inc. All rights reserved.

• B cell infiltration more closely associated with survival than T cell presence in multiple cancers
• Success of I/O therapies appears to be associated with coordinated response including B cells and TLS in the unique context of each patient's tumor microenvironment
• However, specificity of the B cell immune repertoire has not been explored beyond known tumor antigens

Survival in Melanoma Patients

Cabrita et al, Nature (2020)

5